BioVie (NASDAQ:BIVI – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.03, Zacks reports.
BioVie Stock Performance
Shares of NASDAQ BIVI traded down $0.05 during midday trading on Wednesday, reaching $1.27. The company’s stock had a trading volume of 34,557 shares, compared to its average volume of 93,229. BioVie has a fifty-two week low of $1.06 and a fifty-two week high of $12.10. The business’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.40. The company has a market cap of $9.58 million, a P/E ratio of -0.39 and a beta of 0.72.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioVie in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, BioVie has an average rating of “Sell”.
Hedge Funds Weigh In On BioVie
A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in BioVie in the 4th quarter valued at $25,000. Two Sigma Investments LP bought a new stake in shares of BioVie during the 3rd quarter valued at $62,000. Squarepoint Ops LLC acquired a new stake in shares of BioVie during the 3rd quarter worth $63,000. NewEdge Advisors LLC grew its holdings in shares of BioVie by 283.7% during the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of BioVie in the second quarter worth $57,000. Institutional investors own 4.59% of the company’s stock.
About BioVie
BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.
The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.
Further Reading
- Five stocks we like better than BioVie
- How Bad Could Tesla’s Cybertruck Recall Be for Shares?
- Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
- Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
